CAR‐T therapy as a consolidation in remission B‐ALL patients with poor prognosis

BACKGROUND: To date, almost all studies regarding chimeric antigen receptor (CAR)‐T cell therapy for B‐cell acute lymphoblastic leukemia (B‐ALL) were performed in refractory/relapsed (r/r) or minimal residual disease‐positive patients. CAR‐T therapy in remission patients has not been reported. AIM:...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Zhichao, Lin, Yuehui, Liu, Dan, Tong, Chunrong, Liu, Shuangyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575491/
https://www.ncbi.nlm.nih.gov/pubmed/35995579
http://dx.doi.org/10.1002/cnr2.1706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575491/
https://www.ncbi.nlm.nih.gov/pubmed/35995579
http://dx.doi.org/10.1002/cnr2.1706

Ejemplares similares